Clene Nanomedicine's Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 TrialGlobeNewsWire • 01/18/22
Clene Nanomedicine's Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across EuropeGlobeNewsWire • 12/15/21
Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MNDGlobeNewsWire • 12/10/21
Clene Nanomedicine's RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MNDGlobeNewsWire • 12/07/21
Clene Inc. (CLNN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/02/21
Wall Street Analysts Believe Clene Inc. (CLNN) Could Rally 288%: Here's is How to TradeZacks Investment Research • 12/02/21
Clene's Amyotrophic Lateral Sclerosis Candidate Shows Favorable Impact On Disease ProgressionBenzinga • 12/01/21
Does Clene Inc. (CLNN) Have the Potential to Rally 238% as Wall Street Analysts Expect?Zacks Investment Research • 11/16/21
Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform TrialGlobeNewsWire • 11/15/21
Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral SclerosisGlobeNewsWire • 09/23/21
Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021GlobeNewsWire • 09/17/21
Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021GlobeNewsWire • 09/09/21
Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's, Multiple SclerosisBenzinga • 08/05/21
Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson's Disease and Multiple SclerosisGlobeNewsWire • 08/05/21
Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with AgingGlobeNewsWire • 05/17/21